Key clinical point: Patients with early onset cancers have an increased prevalence of germline mutations and would benefit from genetic testing, according to researchers.
Major finding: The prevalence of germline mutations was significantly higher in early onset cancer patients versus young adult cancer patients (21% vs. 13%; P = .002).
Study details: A prospective germline analysis of samples from 1,201 patients.
Disclosures: This study was partially funded by the Precision, Interception and Prevention Program, the Robert and Katie Niehaus Center for Inherited Cancer Genomics, the Marie-Josee and Henry R. Kravis Center for Molecular Oncology, and a National Cancer Institute Cancer Center Core Grant. Dr. Stadler reported that an immediate family member has relationships with Allergan, Adverum Biotechnologies, Alimera Sciences, and several other companies.
Stadler Z et al. AACR 2020, Abstract 1122.